Skip to main content

Bothell biotech firm faces delisting from Nasdaq again

Cocrystal Pharma has failed to maintain the $1 minimum bid price for its common stock for 30 straight business days, in violation of the Nasdaq's listing rule. The company could have up to a year to get back on track.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.